Preoperative characteristics of men with unfavorable high-Gleason prostate cancer at radical prostatectomy

Urologic Oncology: Seminars and Original Investigations

Volumn 31, Issue 5, 2013, Pages 589-594

  Pierorazio, Phillip M ^a   Lin, Brian M ^a   Mullins, Jeffrey K ^a   Hyndman, M Eric ^a   Schaeffer, Edward M ^a   Han, Misop ^a   Partin, Alan W ^a   Pavlovich, Christian P ^a  

^a DEPARTMENT OF PATHOLOGY   (United States)

Author keywords

Gleason sum; High risk; Intermediate risk; Outcomes; Prostate cancer

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; CANCER GRADING; CANCER SURVIVAL; GLEASON SCORE; HUMAN; KAPLAN MEIER METHOD; MAJOR CLINICAL STUDY; MALE; PREOPERATIVE PERIOD; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATECTOMY; TUMOR INVASION;

ADULT; AGED; BIOPSY; DISEASE-FREE SURVIVAL; HUMANS; KAPLAN-MEIER ESTIMATE; LOGISTIC MODELS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM GRADING; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PREOPERATIVE PERIOD; PROGNOSIS; PROSTATE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; TIME FACTORS; TREATMENT OUTCOME;

EID: 84879461409     PISSN: 10781439     EISSN: 18732496     Source Type: Journal    
DOI: 10.1016/j.urolonc.2011.05.002     Document Type: Article

References (27)

1. Cooperberg M.R., Lubeck D.P., Mehta S.S., et al. Time trends in clinical risk stratification for prostate cancer: Implications for outcomes (data from CaPSURE). J Urol 2003, 170:S21-S25.
2. Han M., Partin A.W., Pound C.R., et al. Long-term biochemical disease-free and cancer-specific survival following anatomic radical retropubic prostatectomy. The 15-year Johns Hopkins experience. Urol Clin North Am 2001, 28:555-565.
3. D'Amico A.V., Whittington R., Malkowicz S.B., et al. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA 1998, 280:969-974.
4. Kattan M.W., Eastham J.A., Stapleton A.M., et al. A preoperative nomogram for disease recurrence following radical prostatectomy for prostate cancer. J Natl Cancer Inst 1998, 90:766-771.
5. Kattan M.W., Wheeler T.M., Scardino P.T. Postoperative nomogram for disease recurrence after radical prostatectomy for prostate cancer. J Clin Oncol 1999, 17:1499-1507.
6. Partin A.W., Yoo J., Carter H.B., et al. The use of prostate specific antigen, clinical stage, and Gleason score to predict pathological stage in men with localized prostate cancer. J Urol 1993, 150:110-114.
7. Grossfeld G.D., Latini D.M., Lubeck D.P., et al. Predicting recurrence after radical prostatectomy for patients with high risk prostate cancer. J Urol 2003, 169:157-163.
8. Pound C.R., Partin A.W., Epstein J.I., et al. Prostate-specific antigen after anatomic radical retropubic prostatectomy. Patterns of recurrence and cancer control. Urol Clin North Am 1997, 24:395-406.
9. Partin A.W., Kattan M.W., Subong E.N., et al. Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer. A multi-institutional update. JAMA 1997, 277:1445-1451.
10. Bastian P.J., Gonzalgo M.L., Aronson W.J., et al. Clinical and pathologic outcome after radical prostatectomy for prostate cancer patients with a preoperative Gleason sum of 8 to 10. Cancer 2006, 107:1265-1272.
11. Pierorazio P.M., Guzzo T.J., Han M., et al. Long-term survival after radical prostatectomy for men with high Gleason sum in pathologic specimen. Urology 2010, 76:715-721.
12. Makarov D.V., Trock B.J., Humphreys E.B., et al. Updated nomogram to predict pathologic stage of prostate cancer given prostate-specific antigen level, clinical stage, and biopsy Gleason score (Partin tables) based on cases from 2000 to 2005. Urology 2007, 69:1095-1101.
13. Kattan M.W., Stapleton A.M., Wheeler T.M., et al. Evaluation of a nomogram used to predict the pathologic stage of clinically localized prostate carcinoma. Cancer 1997, 79:528-537.
14. Kattan M.W., Vickers A.J., Yu C., et al. Preoperative and postoperative nomograms incorporating surgeon experience for clinically localized prostate cancer. Cancer 2009, 115:1005-1010.
15. Sebo T.J., Bock B.J., Cheville J.C., et al. The percent of cores positive for cancer in prostate needle biopsy specimens is strongly predictive of tumor stage and volume at radical prostatectomy. J Urol 2000, 163:174-178.
16. Gancarczyk K.J., Wu H., McLeod D.G., et al. Using the percentage of biopsy cores positive for cancer, pretreatment PSA, and highest biopsy Gleason sum to predict pathologic stage after radical prostatectomy: The Center for Prostate Disease Research nomograms. Urology 2003, 61:589-595.
17. Lotan Y., Shariat S.F., Khoddami S.M., et al. The percent of biopsy cores positive for cancer is a predictor of advanced pathologic stage and poor clinical outcomes in patients treated with radical prostatectomy. J Urol 2004, 171:2209-2214.
18. Ohori M., Kattan M.W., Koh H., et al. Predicting the presence and side of extracapsular extension: A nomogram for staging prostate cancer. J Urol 2004, 171:1844-1849.
19. Mortensen M.M., Mortensen P.S., Borre M. Percentage of tumor-positive biopsy cores: An independent predictor of extraprostatic disease. Scand J Urol Nephrol 2009, 43:109-113.
20. Hernandez D.J., Nielsen M.E., Han M., et al. Natural history of pathologically organ-confined (pT2), Gleason score 6 or less, prostate cancer after radical prostatectomy. Urology 2008, 72:172-176.
21. Terris M.K. Prostate biopsy strategies: Past, present, and future. Urol Clin North Am 2002, 29:205-212.
22. Eastham J.A., Kattan M.W., Rogers E., et al. Risk factors for urinary incontinence after radical prostatectomy. J Urol 1996, 156:1707-1713.
23. Wei J.T., Dunn R.L., Marcovich R., et al. Prospective assessment of patient reported urinary continence after radical prostatectomy. J Urol 2000, 164:744-748.
24. Karakiewicz P.I., Tanguay S., Kattan M.W., et al. Erectile and urinary dysfunction after radical prostatectomy for prostate cancer in Quebec: A population-based study of 2,415 men. Eur Urol 2004, 46:188-194.
25. Stanford J.L., Feng Z., Hamilton A.S., et al. Urinary and sexual function after radical prostatectomy for clinically localized prostate cancer: The Prostate Cancer Outcomes Study. JAMA 2000, 283:354-360.
26. Van der Kwast T.H., Bolla M., Van Poppel H., et al. Identification of patients with prostate cancer who benefit from immediate postoperative radiotherapy: EORTC 22911. J Clin Oncol 2007, 25:4178-4186.
27. Wiegel T., Bottke D., Steiner U., et al. Phase III postoperative adjuvant radiotherapy after radical prostatectomy compared with radical prostatectomy alone in pT3 prostate cancer with postoperative undetectable prostate-specific antigen: ARO 96-02/AUO AP 09/95. J Clin Oncol 2009, 7:2924-2930.